Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH505TF gp120 + GLA-SE
- Development stage
- Phase 1
- Lead developer
- Duke Human Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CH505TF gp120 + GLA-SE is an experimental HIV-1 vaccine candidate consisting of a recombinant HIV-1 envelope (Env) protein immunogen formulated with a synthetic adjuvant. The active antigen, CH505TF gp120, is derived from a clade C transmitted/founder (TF) virus, specifically designed to trigger the development of B-cell precursors that can eventually mature into broadly neutralizing antibodies (bnAbs). The vaccine is adjuvanted with GLA-SE, an oil-in-water stable emulsion containing glucopyranosyl lipid A (GLA), which acts as a synthetic Toll-like receptor 4 (TLR4) agonist to enhance the innate and adaptive immune responses. Developed by the HIV Vaccine Trials Network (HVTN) in collaboration with the Duke Human Vaccine Institute and the Infectious Disease Research Institute (IDRI), the vaccine has been evaluated in the HVTN 135 Phase 1 trial to assess its safety and immunogenicity in healthy, HIV-exposed uninfected infants.
- Other names
- HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SECH505TF gp120/GLA-SE
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CXCR4 (C-X-C motif chemokine receptor 4)CD4 (T lymphocyte surface antigen)HS (Heparan sulfate)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on CH505TF gp120 + GLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH505TF gp120 + GLA-SE.